Overview

• Lilly said it will spend more than $1 billion over the next several years to expand supply by partnering with Indian contract manufacturers.
• A new Manufacturing & Quality hub in Hyderabad will oversee the local contract network, with immediate hiring across engineering, chemistry, analytics, quality and management roles.
• The company does not currently operate its own manufacturing facility in India and is engaging established local producers of complex drugs and injectables.
• The collaborations aim to increase availability of treatments for obesity and diabetes as well as Alzheimer’s, cancer and autoimmune conditions, following the India launch of Mounjaro this year.
• The India plan extends Lilly’s broader capacity expansion, including a recent $5 billion Virginia facility under a $27 billion U.S. buildout, with Reuters noting new U.S. drug import tariffs and prospective GLP-1 competition from Indian generics.